You have requested access to member-only content.

Medicare reissues guidance on specimen validity testing for drug screening

CMS recently released MLN Matters SE18001 to provide healthcare practitioners with instructions and coding guidance for specimen validity when performed and billed in combination with drug testing. The article was issued to remind laboratories and other providers performing urine drug testing that specimen validity testing (SVT) is not separately billable.

This is an excerpt from member-only content. Please log in or become a member.

Not a member? Join now!

Revenue Cycle Advisor is the key to your organization's Medicare regulatory news and education. It combines all of HCPro's Medicare regulatory and reimbursement resources into one handy and easy-to-access portal. News is not just repeated from other sources. It is analyzed by our Medicare experts so professionals can comprehend any new rule updates thoroughly.

For questions and support, please call customer service: 800-650-6787.